Smith & Nephew/$SNN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Smith & Nephew

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Ticker

$SNN
Sector

Primary listing

NYSE

Employees

17,000

Smith & Nephew Metrics

BasicAdvanced
$16B
66.97
$0.56
0.62
$0.72
2.39%

What the Analysts think about Smith & Nephew

Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.

Bulls say / Bears say

Smith & Nephew’s first-half trading profit surged, and a $500 million share buyback announcement pushed the stock up 15.3%, demonstrating investor confidence in the company's profit trajectory. (Reuters)
For full-year 2024, the company achieved revenue growth of 4.7% to $5.81 billion and adjusted EPS growth of 1.7% to 84.3 cents, exceeding analyst expectations and supporting guidance for 5% revenue growth and a 19–20% trading profit margin. (FT)
Operational efficiency and cost savings produced strong interim results, enabling a $500 million share buyback and fully offsetting an anticipated $15–20 million tariff hit, underscoring robust cash flow and resilience. (FT)
Setbacks in the China market due to healthcare cost controls and increased local competition have dampened growth prospects, limiting recovery in an important emerging market. (FT)
Ongoing activism and shareholder calls for a company break-up highlight continued concerns about the underperforming orthopaedics division, despite recent strategic advances. (FT)
Expected U.S. tariffs will create a $15–20 million cost headwind, threatening the company’s target for margin expansion in 2025. (FT)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.

Smith & Nephew Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Smith & Nephew Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SNN

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

Oct3
Smith & Nephew
DividendEx-dividend
Nov7
Smith & Nephew
DividendPayment
$0.30Per share
FAQs